Assessment of the cytokine profile in psoriasis patients against the background of an immune-modulating therapy


The authors examined the clinical effect and dynamics of immunological indices (IL-1ƒ, IL-6, TNF-ƒ, IFN-ƒ) at the progressing
and stationary stages of psoriasis with the administration of Stemokin®. A reliable reduction of IL-1ƒ, TNF-ƒ и IFN-ƒ was observed
against the background of treatment and was accompanied with an evident clinical effect. Two variants of the immune system
response were revealed for the complex therapy.


  1. Мордовцев В.Н., Суколин Г.И., Сергеев А.С. Эпидемиология и генетика псориаза. Симпозиум по псориазу дерматовенеро- логов социалистических стран, 3-й. М., 1987; 89.
  2. Baker H. Psoriasisclinical features. Br Med J 1994; 3: 231-233.
  3. Elder J.T., Henseler T., Christophers E. The genetis of psoriasis. Arch Dermatol 1994; 130: 216-224.
  4. Farber E.M. Infantile psoriasis: a follow-up study. Pediatr Dermatol 1986; 3: 3: 237-243.
  5. Matthews D., Powles A.V., Fry L., Williamson. Conformation of genetic heterogeneity in familial psoriais. J Invest Dermatol 1995; 105: 3: 457-461.
  6. Roenigk H.H., Maibach H.I. Psoriasis. Second edition, revised and expanded. New York-Basel-Hong Kong: Marcel De-kker 1991; 992.
  7. Кацамбас А.Д., Лотти Т.М. Европейское руководство по лече- нию дерматологических заболеваний. М. 2008.
  8. Довжанский С.И., Пинсон И.Я. Генетические и иммунологи- ческие факторы в патогенезе псориаза. Рос. журн. кожн. и ве- нерич. болезней. 2006; 1: 14-18.
  9. Christophers E. The immunopathology of psoriasis and biologic immunotherapy. J. Am. Acad. Dermatol 2003; 49: 44-50.
  10. Павлова О.В. Иммуномодулирующая терапия псориаза у больных с сопутствующим шизотиническим расстройством. Рос. журн. кожн. и венерич. болезней. 2006; 4: 32-35.
  11. Gillitzer R., Ritter U., Spandau U. et al. Differential expression of GRO- and IL-8 mRNA in psoriais: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996; 107: 5: 778-782.
  12. Alice B. Gottlieb Psoriasis: Emerging Therapeuthic Strategies. Nature Reviews Drug Discovery 4 2005; 1: 19-34.
  13. Bromley, S.K., et al. The immunological synapse. Annu. Rev. Immunol 2001; 19: 375-396.
  14. Takematsu H., Tagami H. Interleukin-2, soluble interleukin-2 receptor, and interferon-gamma in the suction blister fluids from psoriatic skin [comments]. Arch Dermarol Res 1990; 282: 149-152.
  15. Yawalkar N, Karlen S, Hunger R et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998; 111: 1053-7.
  16. Gearing AJ, Fincham NJ, Bird CR et al. Cytokines in skin lesions of psoriasis. Cytokine 1990; 2: 68-75.
  17. Prinz JC, Gross B, Vollmer S et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur J Immunol 1994; 24: 593-8.
  18. Quin JZ, Chaturvedi V, Denning MF et al. Role of NF-kappaB in the apoptotic-resistant phenotype of keratinocytes. J Biol Chem 1999; 274: 37957-64.
  19. Ruckert R, Asadullah K, Seifert M et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis. J Immunol 2000; 165: 2240-50.
  20. Борисов И.В. Клинико-иммунологическое обоснование па- тогенетической терапии генитального герпеса. Автореф. дис… канд. мед. наук. М., 2007.
  21. Левшин Р.Н., Бобынцев И.И., Силина Л.В. Современные пред- ставления об иммунопатогенезе псориатической болезни. Кур- ский научно-практический вестник «Человек и его здоровье». 2007; 1: 72-78.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies